CGON CG ONCOLOGY INC

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 20, 2025, at 11:30 am ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: .

Contacts:

Media

Sarah Connors

Vice President, Communications and Patient Advocacy, CG Oncology

(508) 654-2277

Investor Relations

Chau Cheng

Vice President, Investor Relations, CG Oncology

(949) 342-8939



EN
15/05/2025

Underlying

CGONCG ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CG ONCOLOGY INC

 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology to Participate in the 2025 RBC Capital Markets Global Heal...

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 20, 2025, at 11:30 am ET. Interested parties can access the live audio webcast for this c...

15h / 6m 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology Reports First Quarter 2025 Financial Results and Provides ...

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretos...

May 13, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the Fir...

SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCHAUMBURG, Ill. and IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and communit...

May 1, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Coho...

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events...

April 26, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Mo...

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NM...

April 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch